Sutro Biopharma (STU:S090) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


STU:S090 Sutro Biopharma Inc STU:S090
45 GF Score
Price €6.24
GF Value €2.66
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sutro Biopharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:S090 vs CCCC, OCGN, FULC: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Sutro Biopharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Margin of Safety % (DCF Earnings Based) falls into.


STU:S090
45GF Score
Sutro Biopharma Inc STU:S090
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sutro Biopharma (STU:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €6.24 is trading 134.4% above its estimated GF Value™ of €2.66.

Key valuation signals for STU:S090:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.66 vs. price of €6.24 (134.4% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USAS090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STU:S090

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.24
Price
€2.66
GF Value